HOME >> BIOLOGY >> NEWS
Cetuximab and irinotecan combination increases survival in metastatic colorectal cancer

LOS ANGELES A phase III trial of 1,298 colorectal cancer patients has found that a combination of the drugs cetuximab (Erbitux) and irinotecan showed a significant improvement in progression-free survival over just irinotecan alone, according to an international team of researchers.

The Erbitux Plus Irinotecan in Colorectal Cancer (EPIC) study looked at survival in metastatic colorectal cancer patients who had already shown resistance to conventional therapies. The research was presented today at the 2007 Annual Meeting of the American Association for Cancer Research.

By the end of the study, a significantly larger number of patients who received the combination of cetuximab, an antibody against the epidermal growth factor and irinotecan, an enzyme-inhibiting cancer drug, survived without their cancers progressing further. The tumor response rate in this group was also significantly higher. The study was sponsored, in part, by Bristol-Myers Squibb and Merck KGaA.

"Patients who received both cetuximab and irinotecan experienced longer periods of time spent, on average, without further progression of the disease," said Alberto F. Sobrero, M.D., of the San Martino Hospital's Department of Medical Oncology in Genoa, Italy. "From a patient perspective, any improvement in progression-free survival, as well as tumor shrinkage, is worthwhile. These data confirm that, despite a moderate increase in side effects, cetuximab is a key therapeutic agent in the optimal treatment of advanced colorectal cancer."

The EPIC trial was designed to study the overall survival in patients treated with both cetuximab and irinotecan, with secondary objectives that include response rate and progression-free survival. Patients eligible in the trial had to have shown resistance to the drug oxaliplatin, a platinum-based therapy commonly used in the treatment of colorectal cancer.

The trial participants, enrolled from cancer centers across Eu
'"/>

Contact: Staci Vernick Goldberg
goldberg@aacr.org
267-646-0616
American Association for Cancer Research
16-Apr-2007


Page: 1 2

Related biology news :

1. Cetuximab increases survival in advanced colorectal cancer patients, study shows
2. New study suggests promising drug combinations for sleeping sickness
3. Cost-effectiveness study of three antimalarial drug combinations in Tanzania
4. Recombination protein dynamics observed with single monomer resolution
5. AVELOX as effective as multi-dose combination therapy for intra-abdominal infections
6. New combination treatment induces regression of prostate cancer
7. Avelox as effective as Levofloxacin combination therapy for severe community-acquired pneumonia
8. New observational study suggests use of combination vaccines may improve immunization coverage rates in infants
9. Pesticide combinations imperil frogs, probably contribute to amphibian decline
10. Study shows combination of immune substances to be safe
11. Immune cell receptors act in combination to regulate attack

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/3/2020)... ... 2020 , ... Accumen Inc. is helping healthcare get better, ... Solutions, to provide COVID-19 saliva testing kits nationally. , “Accumen has been ... 10 years. Early in the COVID-19 crisis, we identified supply chain gaps and ...
(Date:7/18/2020)... TORONTO (PRWEB) , ... July 17, 2020 , ... Commercial ... hangs on pharma’s ability to discover a COVID cure or vaccine, the global economic ... competitive and price pressure is not going away and capturing full value from every ...
(Date:7/2/2020)... Md. (PRWEB) , ... July ... ... Molecular Biology Systems, B.V. (MBS) has announced a publication detailing the use ... one-step reverse transcription polymerase chain reaction (RT-PCR) in 16 minutes. The article, ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... ... “We are thrilled to deliver this new technology to the industry” said ... on the market and we were pleased that the IFT jury recognized that.” reFRESH™ ... creating a natural way to extend the shelf life and improve the safety of ...
(Date:7/10/2020)... ... 2020 , ... Bode Technology, a leading provider ... through its COVID-19 testing service, Bode-CARES . Bode-CARES combines high-volume clinical testing ... provides a turnkey solution that includes a comprehensive collection and virus-management program for ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage ... Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson ... product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine at ...
(Date:7/1/2020)... ... June 29, 2020 , ... ... date growth of 40% in 2020, despite many obstacles created as a result ... to increase revenue for its partnered medical practices and medical manufacturers by expanding ...
Breaking Biology Technology:
Cached News: